Chemistry of Tumour Targeted T1 Based MRI Contrast Agents

Nazila Kamaly, Andrew D. Miller, Jimmy D. Bell

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

For effective tumour imaging by magnetic resonance imaging (MRI) there is a clear need to develop organ, tissue and cell specific contrast agents that can selectively bind to tumour biomarkers. The versatility of a range of bioconjugation techniques and facile coupling chemistries has facilitated the synthesis of MRI contrast agents bearing tumour targeting moieties that comprise small molecule affinity ligands, peptides, antibodies and even proteins. The aim of this review is to describe the development and implementation of tumour targeted T(1) MRI contrast agents, with an emphasis on the chemistry used to modify pre-existing clinical MRI contrast agents for targeted tumour imaging.
Original languageEnglish
JournalCurrent Topics in Medicinal Chemistry
Volume10
Issue number12
Pages (from-to)1158-1183
ISSN1568-0266
Publication statusPublished - 2010
Externally publishedYes

Keywords

  • MRI
  • MRI contrast agents
  • Gadolinium
  • Cancer
  • Tumour
  • Tumour targeting
  • T1 contrast agents
  • Nanoparticles
  • Nanomedicine
  • Paramagnetic contrast agents

Cite this